+547.1%
GLW vs MRNA
+554.4%
-7.4%
-51.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.0% | +5.4% | -3.4% | +1.9% |
| 7D | +7.8% | -1.1% | +8.9% | +7.9% |
| 30D | -0.4% | +126.1% | -126.6% | -5.4% |
| 3M | -5.6% | +190.0% | -195.6% | -12.2% |
| 6M | +26.7% | +157.2% | -130.5% | +18.6% |
| YTD | +91.0% | +388.2% | -297.2% | +70.6% |
| 1Y | +122.4% | +467.0% | -344.6% | +96.1% |
| 3Y | +471.0% | +36.1% | +434.9% | +434.1% |
| 5Y | +385.6% | -68.0% | +453.6% | +363.4% |
| All | +547.1% | +554.4% | -7.4% | +481.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling